Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Diagnosis of DED with Severe Keratitis who have not improved despite regular use of tear substitutes by an ophthalmologist, at least 2 months previously.~* Not stable (as defined by the two items below) under at least 2 months of constant and regular use of artificial tears (at least 4 drops a day)~* Fluorescein corneal staining ≥ 2 (Oxford scale) in both eyes.~* DEQ-5 \> 6 points~* Use of at least 4 times daily of an ocular artificial tears.~* Any concomitant medication that may affect DED, ocular surface condition or vision, must have a start date at least 3 months prior to baseline and dosage is not expected to change during the study.~* Best corrected visual acuity (BCVA) of at least 0.1 logMar at 6 meters with each eye.~* Signature of written informed consent form and data protection form.~Exclusion Criteria:~* Known allergy or sensitivity to the study product(s) or its components.~* Any ocular pathology other than DED.~* History of severe ocular inflammation other than that due to DED or infection in the 6 previous months to the study inclusion.~* Any ocular surgery or trauma that may affect corneal sensitivity and/or normal tear distribution in the 6 previous months or any ocular or systemic surgery or procedure planned during the study duration that may affect the study as assessed by principal investigator.~* History of refractive surgery in the previous 18 months.~* Contact lens use in the ONE previous month to study inclusion and during the duration of the study.~* Use of any ocular topical medication for pathologies other than DED.~* Use of any other ocular topical medication for DED other than artificial tears during the last ONE (steroids) or THREE months (ciclosporine, tacrolimus) .~* Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren's syndrome)~* The start date of any systemic medication that may affect DED, ocular surface condition or vision is \< 3 months prior to baseline or a change in dosage is anticipated during the study.~* Occlusion of the lacrimal puncta either surgically or with plugs within one month prior to study, or anticipated use of the same during the study.~* Pregnancy or breastfeeding.~* Current enrolments in an investigational drug or device study or participation in such a study within 30 day of entry into this study at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IKERVIS® (1mg/mL ciclosporin) eye drops (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).